SCHEMBL10196074

SCHEMBL10196074

CCCCC(OCC(COCCC)OCCC)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 2/20 0.32
LPAR3 Q9UBY5 2/20 0.32
TLR2 O60603 7/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12060574 0.85 ENPP2 (0.31) LPAR1LPAR3
SCHEMBL15686246 0.79 TLR2 (0.34) LPAR1LPAR3TLR2
SCHEMBL829055 0.79 ALDH1A1 (0.40) LPAR1LPAR3
SCHEMBL10196084 0.79 TLR2 (0.32) LPAR1LPAR3TLR2
SCHEMBL12628934 0.78 ALDH1A1 (0.45) LPAR1LPAR3
SCHEMBL828854 0.78 TLR2 (0.41) LPAR1LPAR3TLR2
SCHEMBL25078771 0.74 LPAR1 (0.47) LPAR1LPAR3TLR2
SCHEMBL10181716 0.74 LPAR1 (0.47) LPAR1LPAR3TLR2
SCHEMBL13032606 0.74 LPAR1 (0.47) LPAR1LPAR3TLR2
SCHEMBL24470513 0.74 LPAR1 (0.47) LPAR1LPAR3TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170157259-A1 FACTOR VIII POLYMER CONJUGATES BAXTER INTERNATIONAL INC. 2017-06-08 US disclosed
US-20160361430-A1 BLOOD COAGULATION PROTEIN CONJUGATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-15 US disclosed
US-9492555-B2 Nucleophilic catalysts for oxime linkage BAXALTA INCORPORATED (US) 2016-11-15 US disclosed
US-8642737-B2 Nucleophilic catalysts for oxime linkage BAXTER INTERNATIONAL INC. (US) 2014-02-04 US disclosed
US-20140024808-A1 FACTOR VIII POLYMER CONJUGATES BAXTER HEALTHCARE SA (CH) 2014-01-23 US disclosed
US-20130310546-A1 NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME BAXALTA INCORPORATED 2013-11-21 US disclosed
US-20120035344-A1 NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE BAXTER HEALTHCARE S.A. (CH) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035344-A1 NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE LPO, OGA, DAO LPAR1 4103/4885LPAR3 4271/4885TLR2 2159/4885
US-20170157259-A1 FACTOR VIII POLYMER CONJUGATES F8, F13B, F13A1 LPAR1 4216/4885LPAR3 4206/4885TLR2 3836/4885
US-20130310546-A1 NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME OGA, LPO, CA12 LPAR1 4138/4885LPAR3 3840/4885TLR2 1303/4885
US-20160361430-A1 BLOOD COAGULATION PROTEIN CONJUGATES F13B, F12, F2 LPAR1 4625/4885LPAR3 4002/4885TLR2 2499/4885
US-20140024808-A1 FACTOR VIII POLYMER CONJUGATES F8, F13B, F13A1 LPAR1 4216/4885LPAR3 4206/4885TLR2 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.